Bifeprunox

DRUG18 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, Solvay Pharmaceuticals, H. Lundbeck A/S

Conditions

Bipolar DisorderBipolar I DisorderDepression BipolarHealthyPsychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's TypeSchizoaffective DisorderSchizophrenia

Phase 1

Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects

CompletedNCT00581451

Wyeth is now a wholly owned subsidiary of PfizerHealthy

Start: 2007-10-31End: 2008-12-31Target: 144Updated: 2009-07-10

Phase 2

Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

CompletedNCT00139906

Solvay PharmaceuticalsSchizoaffective Disorder, Schizophrenia

Start: 2005-08-31End: 2006-10-31Updated: 2015-01-16

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

CompletedNCT00139919

Solvay PharmaceuticalsBipolar Disorder, Schizoaffective Disorder, Schizophrenia

Start: 2006-01-31End: 2007-10-31Updated: 2015-01-16

PK Effects of Bifeprunox & Valproate in Bipolar I

CompletedNCT00141505

Solvay PharmaceuticalsBipolar I Disorder

Start: 2005-02-28End: 2006-12-31Updated: 2015-01-16

To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

CompletedNCT00141479

Solvay PharmaceuticalsSchizoaffective Disorder, Schizophrenia

Start: 2005-05-31End: 2006-11-30Updated: 2015-01-16

Phase 3

Study Evaluating Bifeprunox in Bipolar Depression

CompletedNCT00134459

Wyeth is now a wholly owned subsidiary of PfizerBipolar Disorder

Start: 2005-06-30End: 2006-05-31Updated: 2013-02-15

Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

TerminatedNCT00160147

Solvay PharmaceuticalsPsychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Start: 2005-12-31End: 2008-01-31Updated: 2015-02-09

Bifeprunox in the Treatment of Schizophrenia

CompletedNCT00193713

Solvay PharmaceuticalsSchizophrenia

Start: 2005-05-31End: 2006-11-30Updated: 2015-01-16

Bifeprunox in the Treatment of Schizophrenia

CompletedNCT00193687

Solvay PharmaceuticalsSchizophrenia

Start: 2005-09-30End: 2008-01-31Updated: 2008-03-24

Patient-reported Outcomes in the Treatment of Schizophrenia

CompletedNCT00230828

Solvay PharmaceuticalsSchizophrenia

Start: 2005-05-31Updated: 2013-09-12

Study Evaluating Bifeprunox in Bipolar Depression

CompletedNCT00245973

Wyeth is now a wholly owned subsidiary of PfizerDepression Bipolar

Start: 2005-06-30End: 2007-10-31Target: 380Updated: 2007-12-05

Open Label Extension Study of Bifeprunox

CompletedNCT00366171

Wyeth is now a wholly owned subsidiary of PfizerSchizophrenia

Start: 2006-11-30End: 2007-10-31Target: 120Updated: 2007-12-27

Study Evaluating Bifeprunox in Patients With Schizophrenia.

TerminatedNCT00366327

Wyeth is now a wholly owned subsidiary of PfizerSchizophrenia

Start: 2007-01-31End: 2008-03-31Target: 400Updated: 2013-02-11

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

TerminatedNCT00366704

Wyeth is now a wholly owned subsidiary of PfizerSchizophrenia

Start: 2006-11-30End: 2008-03-31Target: 400Updated: 2013-02-11

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

TerminatedNCT00396214

Solvay PharmaceuticalsSchizophrenia

Start: 2007-04-30End: 2008-01-31Updated: 2008-06-04

Efficacy of Bifeprunox in Patients With Schizophrenia

TerminatedNCT00658645

H. Lundbeck A/SSchizophrenia

Start: 2008-03-31End: 2009-11-30Updated: 2010-09-27

Efficacy of Bifeprunox in Patients With Schizophrenia

TerminatedNCT00704509

H. Lundbeck A/SSchizophrenia

Start: 2008-06-30End: 2009-11-30Updated: 2010-09-27

Bifeprunox Extension to Extension Study in Patients With Schizophrenia

TerminatedNCT00861497

H. Lundbeck A/SSchizophrenia

Start: 2006-01-31End: 2009-07-31Updated: 2013-09-16